Is the Era of Age-Based Screening Ending? The Risk-Based Revolution in Breast Cancer
In this article
The principle that one size does not fit all is moving into oncology. The WISDOM study and CISNET models have opened the door to an era of smart screening with fewer false alarms and more lives saved.
Consider two women of the same age…
One has no family history of breast cancer, predominantly fatty breasts, and no additional risk factors. The other has dense breast tissue, a first-degree relative diagnosed with cancer at an early age, and high genetic risk. Is it really smart to use the same screening program for both, starting at the same age and performing mammography at the same intervals?
Breast cancer screening has a success story spanning more than 40 years. Yes, screening has increased early diagnosis and helped reduce mortality. But screening also comes at a price: false-positive recalls, unnecessary biopsies, overdiagnosis, and unnecessary stress. That is precisely why, in the scientific community, the idea gaining ground is not more screening, but smarter screening . The recently published WISDOM study and CISNET modeling have brought this transformation to a turning point.
1. Why Did One-Size-Fits-All Screening Become the Standard?
Until now, screening programs have been based almost exclusively on age. Age was one of the strongest predictors of risk and the easiest to apply in public health programs. But in the era of personalized medicine, an average approach is no longer enough. Risk varies widely within the same age group: standard screening is excessive for some (unnecessary radiation or biopsies) and insufficient for others (late diagnosis).
2. What Is Risk-Based Screening?
Risk-based, personalized screening says: “The starting age, frequency, and method of screening (mammography, MRI, etc.) should be determined by the individual's measurable biological risk.”
3. The Evidence: WISDOM and CISNET
Two major studies published in recent weeks (December 2025 - January 2026) demonstrated that this new approach is more than a theory.
This randomized study, which adjusted screening frequency according to risk categories, tested the fear that screening less might mean missing cancer.
It simulated the long-term outcomes of strategies based on 5-year absolute risk compared with conventional age-based screening.
4. Why Now? The 3 Forces Driving Change
Three technological advances make this transformation possible:
- Risk Calculators (BCSC): Models validated with very large datasets are now ready for clinical use.
- The Democratization of Genetics: Tests such as polygenic risk scores (PRS) are no longer merely research topics but tools used to determine risk.
- Artificial Intelligence (AI): By improving imaging quality and interpretation speed, AI makes the workload of personalized protocols manageable.
The Critical Question: Could Inequality Increase?
The greatest risk of risk-based screening is healthcare inequality. Breast cancer mortality is known to be higher among Black women. If risk prediction models do not work correctly in different ethnic groups, such as people of Asian or African ancestry, these groups may experience delayed diagnosis. The WISDOM 2.0 study aims to increase diversity precisely to prevent this bias.
5. What Will Change in Clinical Practice?
This new era will fundamentally change the dialogue between physicians and patients.
Risk assessment will be a natural part of the consultation rather than an additional task. MRI use will become systematic in high-risk patients, while excessive screening can be reduced in low-risk patients without guilt.
The belief that having an annual mammogram makes one safe will give way to awareness of one's individual risk. False alarms and biopsy-related stress will decrease, while high-risk patients will receive the intensive follow-up they deserve.
DROZDOGAN Academy Commentary
We are witnessing the end of one era and the beginning of another in breast cancer screening. For years, we debated whether screening was necessary. Today the question has changed: “Who should be screened, when, and how?”
The WISDOM and CISNET data send us a clear message: More screening is not always better; smarter screening is better. Instead of burdening low-risk individuals, we should use our resources to follow high-risk people more closely, including those with genetic risk or dense breasts. This is required by both science and conscience.
- Medscape Medical News – Risk-Based Breast Cancer Screening Nears a Turning Point (February 06, 2026).
- Esserman LJ et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA (December 2025).
- Alagoz O et al. Five-Year Absolute Risk–Based and Age-Based Breast Cancer Screening in the US. JAMA Network Open (January 2026).
- Pace LE, Hans M. Risk-Based Mammography Screening (Commentary). JAMA Network Open (2026).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.